Takeda Pharmaceutical
Valuation each multiple against its own 5-year range
Vs. peers Drug Manufacturers - Specialty & Generic
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Takeda Pharmaceutical (TAK) | 69.76B | 311.00 | 1.50 | 1.44% |
| Teva Pharmaceutical Industries (TEVA) | 45.77B | 91.23 | 5.74 | 0.00% |
| Haleon (HLN) | 39.76B | 19.14 | 1.85 | 2.09% |
| Zoetis (ZTS) | 32.14B | 13.34 | 9.73 | 2.64% |
| United Therapeutics (UTHR) | 23.63B | 20.94 | 3.76 | 0.00% |
| Viatris (VTRS) | 22.50B | -37.04 | 1.64 | 2.45% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 3.5% above Morningstar's fair value estimate.
Fair value
Takeda Pharmaceutical Co Ltd receives a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a minor 2% premium over our quantitative fair value estimate of $21.02 per share, which has a low uncertainty rating.
The company's lack of growth weakens our estimated valuation. Stagnant revenue and earnings growth indicates a company's challenges in increasing market share and profitability. Reflecting the firm's growth is its revenue 3-year growth of 4.6%, which ranks in the bottom 45% compared with global peers. Unfavorable revenue growth over the last three years could be considered concerning when it comes to the future revenue and cash flow potential of the business. We believe this is a sign that shares could be expensive.
Alternatively, the firm's valuation metrics are reassuring. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of 70.8%, a core component of valuation, falls in the top 45% compared with global peers. The market price is low relative to the book (accounting) value of the company's equity, which, despite our unfavorable price/fair value ratio, is a positive attribute.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.
Economic moat
This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
By Quantitative Equity Report
Quote time 2026-11-20 20:02:19 · For reference only, not investment advice and not tailored to your situation.
Takeda Pharmaceutical discussion 0 comments